French Endocrine Society Guidance on endocrine side effects of immunotherapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
French Endocrine Society Guidance on endocrine side effects of immunotherapy
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume -, Issue -, Pages G1-G18
Publisher
Bioscientifica
Online
2018-10-09
DOI
10.1530/erc-18-0320
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ENDOCRINE SIDE-EFFECTS OF NEW ANTICANCER THERAPIES: OVERALL MONITORING AND CONCLUSIONS
- (2018) F. Castinetti et al. ANNALES D ENDOCRINOLOGIE
- EXPERT OPINIONS ON ADRENAL COMPLICATIONS IN IMMUNOTHERAPY
- (2018) M. Haissaguerre et al. ANNALES D ENDOCRINOLOGIE
- EXPERT OPINIONS ON ENDOCRINE TOXICITY INDUCED BY NEW ANTICANCER THERAPIES: PRECAUTIONS TO BE TAKEN IN PERFORMING AND INTERPRETING HORMONAL ASSAYS UNDER IMMUNOTHERAPY
- (2018) Najiba Lahlou et al. ANNALES D ENDOCRINOLOGIE
- INTRODUCTION TO EXPERT OPINION ON ENDOCRINE COMPLICATIONS OF NEW ANTI-CANCER THERAPIES
- (2018) Frederic Castinetti et al. ANNALES D ENDOCRINOLOGIE
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Anti–Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?
- (2018) Lucien Marchand et al. DIABETES CARE
- Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect
- (2018) S. Hescot et al. EUROPEAN JOURNAL OF CANCER
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy
- (2018) C E Higham et al. Endocrine Connections
- Expert opinion on pituitary complications in immunotherapy
- (2018) Claire Briet et al. ANNALES D ENDOCRINOLOGIE
- Expert opinion on immunotherapy induced diabetes
- (2018) Sarra Smati et al. ANNALES D ENDOCRINOLOGIE
- Expert opinion on thyroid complications in immunotherapy
- (2018) Frederic Illouz et al. ANNALES D ENDOCRINOLOGIE
- Endocrine side effects of cancer immunotherapy
- (2017) Priscilla Cukier et al. ENDOCRINE-RELATED CANCER
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
- (2017) Danae A Delivanis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
- (2017) Georgina V Long et al. LANCET ONCOLOGY
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
- (2017) Frédéric Illouz et al. Cancer Medicine
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
- (2016) Patrizio Caturegli et al. AMERICAN JOURNAL OF PATHOLOGY
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review
- (2016) M.N Joshi et al. CLINICAL ENDOCRINOLOGY
- Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
- (2016) Jeroen de Filette et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Ipilimumab-Induced Adrenalitis
- (2015) Sara Bacanovic et al. CLINICAL NUCLEAR MEDICINE
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy
- (2015) Aurélien Marabelle et al. PEDIATRIC BLOOD & CANCER
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
- (2014) L. Min et al. CLINICAL CANCER RESEARCH
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
- (2013) Francesco Torino et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy
- (2013) A. Lammert et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
- (2013) Stefania Laurent et al. Journal of Translational Medicine
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Update on the diagnosis and management of hypophysitis
- (2013) John D. Carmichael Current Opinion in Endocrinology Diabetes and Obesity
- Ipilimumab-induced autoimmune adrenalitis
- (2013) Le Min et al. Lancet Diabetes & Endocrinology
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family
- (2011) Hélène Bour-Jordan et al. IMMUNOLOGICAL REVIEWS
- Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
- (2010) Le Min et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
- (2009) Troy Dillard et al. Pituitary
- Pituitary autoimmunity: 30 years later
- (2008) Patrizio Caturegli et al. AUTOIMMUNITY REVIEWS
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Interaction of human PD-L1 and B7-1
- (2008) Manish J. Butte et al. MOLECULAR IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now